Absence of Bcl-2 and Fas/CD95/APO-1 predicts the response to immunotherapy in metastatic renal cell carcinoma

Immunotherapy is the only available treatment for metastatic renal cell cancer (RCC), but the response rate is only about 20% and the treatment is occasionally associated with severe adverse effects. Thus, the selection of patients with a high susceptibility to immunotherapy is needed; however, ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Maruyama, R, Yamana, K, Itoi, T, Hara, N, Bilim, V, Nishiyama, T, Takahashi, K, Tomita, Y
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360577/
https://www.ncbi.nlm.nih.gov/pubmed/17031406
http://dx.doi.org/10.1038/sj.bjc.6603359

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360577/
https://www.ncbi.nlm.nih.gov/pubmed/17031406
http://dx.doi.org/10.1038/sj.bjc.6603359

Ejemplares similares